Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

398
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
398
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

127
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
127
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.6K
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

159
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
159
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

116
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
116

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Case of Metastasis or Skipped Nodal Metastasis?

The Australasian journal of dermatology·2025
Same author

Optimization of Pharmacist Resources at a Community Internal Medicine Teaching Hospital: Development of a Tool Through Pharmacist and Physician Expert Panels.

Hospital pharmacy·2025
Same author

Impaired 11β-HSD1 Activity in a Male Patient With Cushing Disease Resulting in Lack of the Full Cushingoid Phenotype.

JCEM case reports·2024
Same author

Evolving Pharmacist Productivity Models.

Hospital pharmacy·2024
Same author

Establishing a Legacy: Considerations for Retiring Leaders.

Hospital pharmacy·2024
Same author

Anthropogenic and Biogenic Contributions to the Organic Composition of Coastal Submicron Sea Spray Aerosol.

Environmental science & technology·2022
Same journal

Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa: A Multicenter Retrospective Cohort Study.

Hospital pharmacy·2026
Same journal

Stability of Diluted Intravenous Metronidazole in 0.9% Sodium Chloride.

Hospital pharmacy·2026
Same journal

Response to Comment on "Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".

Hospital pharmacy·2026
Same journal

Significant Published Articles in 2025 for Pharmacy Nutrition Support Practice.

Hospital pharmacy·2026
Same journal

Comment on "Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".

Hospital pharmacy·2026
Same journal

Comparison of Cystatin C-Based and Serum Creatinine-Based Renal Function Estimates Against Timed Urine Collection in Critically Ill Patients.

Hospital pharmacy·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Evaluating Clinicians' Adoption of Ultrasound-Guided Vascular Cannulation Through Simulation Training
05:04

Author Spotlight: Evaluating Clinicians' Adoption of Ultrasound-Guided Vascular Cannulation Through Simulation Training

Published on: August 9, 2024

1.9K

Enhancing pharmacy practice models through pharmacists' privileging.

Benjamin Philip1, Robert J Weber2

  • 1Senior Pharmacy Resident - Pharmacy Administration.

Hospital Pharmacy
|January 15, 2014
PubMed
Summary
This summary is machine-generated.

Granting clinical privileges to pharmacists in hospitals is essential for patient-centered care and effective medication use. This process supports the integration of pharmacists into patient care teams and accountability for drug therapy outcomes.

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

2.1K

Related Experiment Videos

Last Updated: May 4, 2026

Author Spotlight: Evaluating Clinicians' Adoption of Ultrasound-Guided Vascular Cannulation Through Simulation Training
05:04

Author Spotlight: Evaluating Clinicians' Adoption of Ultrasound-Guided Vascular Cannulation Through Simulation Training

Published on: August 9, 2024

1.9K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

2.1K

Area of Science:

  • Health Services Research
  • Pharmacy Practice
  • Healthcare Administration

Background:

  • Hospital pharmacy practice is evolving towards patient-centered services.
  • New practice models necessitate pharmacists entering into board-approved consult agreements.
  • Institutional privileging of pharmacists is becoming a requirement for advanced practice.

Purpose of the Study:

  • To guide pharmacy leaders in establishing patient-centered services.
  • To focus on the concept and necessity of granting clinical privileges to pharmacists.
  • To improve medication use efficiency and effectiveness through pharmacist integration.

Main Methods:

  • Discussion of the credentialing and privileging process for pharmacists.
  • Emphasis on the role of the pharmacy director in implementing these processes.
  • Highlighting the need for medical staff support for pharmacist privileging.

Main Results:

  • Institutional privileging is necessary as pharmacy practice models change.
  • Pharmacy directors must understand and apply the credentialing and privileging process.
  • Active support from hospital medical staff is crucial for successful implementation.

Conclusions:

  • Pharmacist clinical privileges are key to advancing patient-centered care in hospitals.
  • Successful implementation requires understanding the privileging process and medical staff support.
  • This supports the Pharmacy Practice Model Initiative's goals for pharmacist integration and accountability.